Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Full Circle: David Hung Looks Forward To Axovant's Alzheimer's Data, Reflects On Medivation

Jun 27 2017

• By Mandy Jackson

Compass and keyboard

Related Content

Xtandi Sales Disappoint Pfizer, Returning Focus To The High-Priced Deal

May 02 2017

Appointments: Sanofi, Recipharm, Axovant, e-Therapeutics & Diplomat

Apr 14 2017

New Xtandi data bolster case for pre-chemo use

Jan 23 2015

Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer

Jun 12 2017

Medivation Rejects Sanofi's Latest Bid, But Enters Confidential Negotiations

Jul 06 2016

Can Axovant's RVT-1 Redeem 5HT6 Class After Lundbeck's Idalopirdine Failure?

Feb 09 2017

Pfizer’s $14bn Medivation Buyout Shows How Far Pharma Will Go In Oncology

Aug 22 2016

Janssen's Zytiga Shines At ASCO But Prostate Cancer Pipeline Progress May Dampen Impact

Jun 05 2017

Related Companies

Sio Gene Therapies, Inc.

Medivation, Inc.

Pfizer Inc.

Sanofi

H. Lundbeck A/S

Otsuka Holdings Co., Ltd.

Johnson & Johnson

Astellas Pharma, Inc.

Roivant Sciences Ltd.

Additional Topics

Deals Companies Business Strategies Strategy Commercial BioPharmaceutical

More from Deals

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window